文献速递免疫规划传染病防控与疫情报告妇幼与学校卫生

MVA-BN疫苗在刚果民主共和国4至<24月龄儿童中的3期随机双盲临床试验方案

Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.
PubMed 文献 · Vaccine · 2026-06-29

本方案描述PregInPoxVac试验,在刚果民主共和国mpox流行区招募344名4至<24月龄健康儿童,随机1:1接受两剂全剂量(0.5 mL)或半剂量(0.25 mL)MVA-BN疫苗皮下接种,间隔28天。主要目标是通过中和抗体应答的层级非劣效分析,比较婴儿方案与POX-MVA-045成人全剂量参考队列的免疫原性和安全性。

要点

  • 评估婴儿全剂量与半剂量MVA-BN方案对比成人全剂量参考的非劣效性。
  • 主要免疫原性终点为中和抗体应答的层级非劣效分析。
  • 安全性随访包括每剂后7天征集性AE、28天非征集性AE及至第二剂后12个月SAE。

核心结论

  • 本试验旨在评估婴儿两种MVA-BN接种方案相较于成人全剂量参考方案的免疫原性和安全性,以指导未来儿科疫苗接种策略。

研究设计与样本

  • 3期随机双盲疫苗试验,在刚果民主共和国Boende综合转诊医院招募344名4至<24月龄健康儿童。
  • 参与者按1:1随机接受两剂全剂量(0.5 mL)或两剂半剂量(0.25 mL)MVA-BN疫苗,皮下接种,间隔28天。
  • 免疫原性和安全性将与POX-MVA-045试验中成人全剂量参考队列进行比较。

主要发现

  • 主要分析为婴儿全剂量和半剂量方案与成人全剂量参考队列中和抗体应答的层级非劣效分析。
  • 次要分析包括婴儿全剂量与半剂量方案间的免疫原性和安全性比较,以及婴儿与成人总结合抗体比较。

关键数值与推荐

  • 全剂量为0.5 mL,半剂量为0.25 mL,均皮下接种,间隔28天。
  • 征集性不良事件记录至每剂接种后7天或事件缓解;非征集性不良事件记录至每剂后28天或事件缓解。
  • 医学 attended 不良事件、特别关注不良事件和严重不良事件从签署知情同意书记录至第二剂后12个月。

临床怎么用

  • 该试验结果将为婴儿mpox疫苗接种的剂量选择和安全性提供依据,支持未来儿科免疫策略的制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This article describes the protocol of the PregInPoxVac vaccine trial, evaluating the safety and immunogenicity of two MVA-BN vaccination regimens (full-dose and half- dose) administered subcutaneously with a 28-day interval in infants aged 4 to <24 months old. Non-inferiority of the full dose and half dose regimens will be compared to adults receiving a full dose regimen as part of the POX-MVA-045 study (ClinicalTrials.govIdentifier:NCT06549530). The PregInPoxVac study is being conducted in Boende, Tshuapa Province, Democratic Republic of the Congo (DRC), a mpox-endemic area; the POX-MVA-045 study is being conducted in Kinshasa, DRC, and Entebbe, Uganda. This is a randomized, double-blind, phase 3 trial assessing two dosing regimens in infants, with immunogenicity and safety compared to a predefined adult reference dataset. METHODS: This is a phase 3, randomized, double-blind vaccine trial. A total of 344 healthy children aged 4 to <24 months will be enrolled at the Boende General Referral Hospital in the DRC. Participants will be randomized in a 1:1 ratio to receive either two full doses (0.5 mL) or two half doses (0.25 mL) of the MVA-BN® vaccine, administered subcutaneously 28 days apart. The primary objective is to evaluate the immunogenicity and safety of the paediatric vaccination regimen compared to the reference adult regimen, as defined in the POX-MVA-045 vaccine trial. Immunogenicity will be assessed through a hierarchical non-inferiority analysis of neutralizing antibody responses comparing full-dose and half-dose regimens in infants with the full-dose adult reference cohort. As a secondary analysis, the immunogenicity and safety observed in full dose infants will be compared to half dose infants. Additionally, total binding antibodies against vaccinia will also be compared between infants and adults as a secondary objective. Solicited adverse events (AEs) will be recorded for 7 days following each injection or until resolution of the event. Unsolicited AEs will be recorded for 28 days following each injection or until resolution of the event. Medically attended AEs (MAAEs), AEs of special interest (AESIs), serious AEs (SAEs) will be recorded from signing of the informed consent through 12 months after the second dose. Participant enrolment was conducted between 29 May and 30 October 2025. ETHICS AND DISSEMINATION: The protocol was approved by the Antwerp University Hospital Committee for Medical Ethics (Approval No. 2025-7480), the National Health Ethics Committee of the DRC Ministry of Health (CNES) (Approval No. 641/CNES/BN/PMMF/2025) and by the Congolese Pharmaceutical Regulatory Authority (ACOREP:Approval No. 556/ACRP/DG/CAB/D15/2025). The trial has been registered on ClinicalTrials.gov (Identifier: NCT06844487).Written informed consent will be obtained from all parents or legal guardians prior to any study-related procedures being performed. The results will be published in peer-reviewed scientific journals and presented at national and international conferences.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tshilumba SM, Ruiz PM, Matuvanga TZ, et al. Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies. Vaccine. 2026. PMID: 42372625. doi:10.1016/j.vaccine.2026.128890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。